Coronavirus (COVID‐19) disease is usually characterised by poorprognosis in patients with diabetes implying that mitigation of the COVID‐19 pandemic risk becomes a priority in patients with type 1 (T1D) or type 2 (T2D) diabetes.1 Despite that COVID‐19 vaccination represents the most powerful tool to mitigate COVID‐19 disease, multiple unresolved issues with regard to the efficacy and durability of COVID‐19 vaccine in patients with diabetes still remain unsolved.
Third dose of COVID-19 vaccine in diabetes. Relevance of good metabolic control to improve its efficacy / Pieralice, Silvia; D'Onofrio, Luca; Pozzilli, Paolo; Buzzetti, Raffaella. - In: DIABETES/METABOLISM RESEARCH AND REVIEWS. - ISSN 1520-7552. - 38:5(2022), pp. 1-3. [10.1002/dmrr.3533]
Third dose of COVID-19 vaccine in diabetes. Relevance of good metabolic control to improve its efficacy
Luca D'Onofrio;Raffaella Buzzetti
2022
Abstract
Coronavirus (COVID‐19) disease is usually characterised by poorprognosis in patients with diabetes implying that mitigation of the COVID‐19 pandemic risk becomes a priority in patients with type 1 (T1D) or type 2 (T2D) diabetes.1 Despite that COVID‐19 vaccination represents the most powerful tool to mitigate COVID‐19 disease, multiple unresolved issues with regard to the efficacy and durability of COVID‐19 vaccine in patients with diabetes still remain unsolved.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pieralice_Third-dose-ofCOVID-19-vaccine_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
152.53 kB
Formato
Adobe PDF
|
152.53 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
